Claims
- 1. A compound of the formula: ##STR7## in which R.sub.1 represents a polyfluoroalkoxy radical and R.sub.2 represents an alkylthio, alkylsulphinyl or alkylsulphonyl radical, it being understood that the alkyl and alkoxy portions contain 1 to 4 carbon atoms in a straight or branched chain, as well as its salts with inorganic or organic acids.
- 2. A compound according to claim 1 for which R.sub.1 represents a trifluoromethoxy, pentafluoroethoxy, 2,2,2-trifluoroethoxy or 1,1,2,2-tetrafluoroethoxy radical.
- 3. A compound according to claim 1 which is 2-imino-3-(3-methylthiopropyl)-6-trifluoromethoxybenzothiazoline.
- 4. A compound according to claim 1 which is (RS)-2-imino-3-(3-methylsulphinylpropyl)-6-trifluoromethoxybenzothiazoline
- 5. A compound according to claim 1 which is 2-imino-3-(3-methylsulphonylpropyl)-6-trifluoromethoxybenzothiazoline.
- 6. A compound of the formula: ##STR8## and salts thereof with inorganic or organic acids; wherein R.sub.1 represents a polyfluoroalkoxy radical, and
- wherein R.sub.2 represents an alkylthio, alkysulphinyl or alkylsulphonyl radical,
- wherein said alkyl and alkoxy portions contain 1 to 4 carbon atoms in a straight or branched chain,
- wherein the imino group is unsubstituted or substituted with a halogenated acyl group having 1 to 7 carbon atoms.
- 7. The compound of claim 6 wherein the halogenated acyl group is selected from the group consisting of trifluoroacetyl and 3-chlorobenzoyl.
- 8. A pharmaceutical composition for the treatment of a medical condition associated with the effects of glutamate which comprises a therapeutically effective amount of a compound of claim 1 in association with a pharmaceutically acceptable carrier.
- 9. The pharmaceutical composition of claim 6 wherein said compound is selected from the group consisting of:
- 2-imino-3-(3-methylthiopropyl)-6-trifluoromethoxybenzothiazoline;
- (RS)-2-imino-3-(3-methylsulphinylpropyl)-6-trifluoromethoxybenzothiazoline; and
- 2-imino-3-(3-methylsulphonylpropyl)-6-trifluoromethoxybenzothiazoline.
- 10. A method for the treatment of a medical condition associated with the effects of glutamate which comprises administering to a subject in need of such treatment an amount of a compound as claimed in claim 1, sufficient to inhibit such effects at least partially.
- 11. The method of claim 10 wherein said medical condition is convulsion.
- 12. A method for the treatment of a medical condition associated with the effects of glutamate which comprises administering to a subject in need of such treatment an amount of a composition as claimed in claim 8.
Priority Claims (1)
Number |
Date |
Country |
Kind |
90 06277 |
May 1990 |
FRX |
|
Parent Case Info
This application is a continuation-in-part of U.S. application Ser. No. 450,231, filed Dec. 13, 1989.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5008280 |
Gueremy |
Apr 1991 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
375510 |
Jun 1990 |
EPX |
Non-Patent Literature Citations (2)
Entry |
March, Advanced Organic Chemistry, pp. 360, 361, 1089, 1090 (1985). |
Greene, Protective Groups in Organic Synthesis pp. 235, 54.55 (1981). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
450231 |
Dec 1989 |
|